Kiora PharmaceuticalsFRA:7EY 34 EV-to-FCF is 0.18 as of Jul. 03, 2026. GuruFocus rates FRA:7EY with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 332 Biotechnology companies, Kiora Pharmaceuticals ranks better than 93.67% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Kiora Pharmaceuticals's Enterprise Value is €-1.62 Mil.
Kiora Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-8.98 Mil. Therefore, Kiora Pharmaceuticals's EV-to-FCF for today is 0.18.
The historical rank and industry rank for Kiora Pharmaceuticals's EV-to-FCF or its related term are showing as below:
FRA:7EY'
s EV-to-FCF Range Over the Past 10 Years
Min: -4.48 Med: -1.26 Max: 1.12
Current: 0.17
During the past 13 years, the highest EV-to-FCF of Kiora Pharmaceuticals was 1.12. The lowest was -4.48. And the median was -1.26.
FRA:7EY's EV-to-FCF is ranked better than 93.67% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs FRA:7EY: 0.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kiora Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Kiora Pharmaceuticals's share price for today is €0.4208.
Kiora Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.327.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kiora Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiora Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Kiora Pharmaceuticals's EV-to-FCF falls into.
Kiora Pharmaceuticals's current Enterprise Value is €-1.62 Mil.
Kiora Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiora Pharmaceuticals (FRA:7EY) has a EV-to-FCF of 0.18 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kiora Pharmaceuticals and its competitors. According to the industry distribution chart, Kiora Pharmaceuticals ranks #21 out of 332 companies in the Biotechnology industry, placing it in the top 6.3%.
Is Kiora Pharmaceuticals' EV-to-FCF too high?
Kiora Pharmaceuticals' current EV-to-FCF is 0.18. The Biotechnology industry median EV-to-FCF is 16.26. Kiora Pharmaceuticals' value of 0.18 is 98.9% below this industry median. Based on the distribution chart, Kiora Pharmaceuticals ranks #21 out of 332 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kiora Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' EV-to-FCF compare to PHIO and PBM?
According to the Biotechnology industry distribution chart, Kiora Pharmaceuticals ranks #21 out of 332 companies for EV-to-FCF. This places Kiora Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.26. Kiora Pharmaceuticals' value of 0.18 is 98.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiora Pharmaceuticals's current EV-to-FCF of 0.18 is 98.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Kiora Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiora Pharmaceuticals's current EV-to-FCF is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (FRA:7EY) has a current EV-to-FCF of 0.18. The current EV-to-FCF is 0.18 and 98.9% below the Biotechnology industry median of 16.26. Kiora Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Kiora Pharmaceuticals (FRA:7EY), the current EV-to-FCF is 0.18 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
34GF Score
Get the complete analysis for FRA:7EY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7EY has been successfully added to your 
